BIO-TECHNE to be Acquired by Merck KGaA for $11.3 Billion in All-Cash Deal
Summary
BIO-TECHNE Corp has entered into a definitive agreement to be acquired by Merck KGaA for $73 per share in an all-cash transaction, valuing the company at $11.3 billion.
Key Events
-
Definitive Acquisition Agreement
Merck KGaA, Darmstadt, Germany, will acquire BIO-TECHNE Corp for US$73 per share in an all-cash transaction.
-
Significant Transaction Value
The acquisition represents a total enterprise value of approximately US$11.3 billion (EUR 9.9 billion).
-
Substantial Premium Offered
The offer price of $73 per share represents a 36% premium to Bio-Techne's one-month volume weighted average trading price.
-
Strategic Rationale
The acquisition aims to strengthen Merck KGaA's leadership in fast-growing life sciences markets, including multi-omics, spatial biology, precision diagnostics, and cell and gene therapy.
Analysis
This 8-K officially announces the definitive agreement for Merck KGaA to acquire BIO-TECHNE Corp for $73 per share in cash, representing an enterprise value of $11.3 billion. This transaction, which follows recent activist investor pressure and news reports, offers a significant premium to shareholders and fundamentally alters the company's future as an independent entity. The deal is expected to close by late 2026 or early 2027, subject to regulatory and shareholder approvals.
At the time of this filing, TECH was trading at $70.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.2B. The 52-week trading range was $43.20 to $72.16. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.